Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
Date:6/16/2008

SEATTLE, June 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced presentation of data at the 2008 Annual European Congress of Rheumatology meeting in Paris demonstrating that repeat administration with TRU-015, Trubion's lead candidate for the treatment of rheumatoid arthritis (RA), continues to produce persistent responses on the American College of Rheumatology (ACR) criteria and consistent pharmacodynamic (PD) effects. In addition, preclinical data presented at the meeting demonstrated that a single dose of SBI-087, a next-generation Small Modular ImmunoPharmaceutical (SMIP(TM)) treatment for RA, resulted in more potent B-cell depletion in peripheral blood and lymphoid tissues than rituximab. Wyeth Pharmaceuticals is developing TRU-015 and SBI-087 in collaboration with Trubion.

Repeated Therapy With TRU-015 Is Well-Tolerated With Consistent PD Profile (OP-0252)

The objective of the ongoing re-treatment study was to evaluate the safety, PD, pharmacokinetics and immunogenicity of TRU-015 for RA with repeated doses after receiving initial administration in a Phase I/IIa study. Patients treated with a single course of 5 mg/kg or higher in a previously conducted TRU-015 Phase I/IIa study were eligible for re-treatment. Patients who received a single infusion of 5 mg/kg received a single infusion of 5 mg/kg upon re-treatment, and those who received higher doses of TRU-015 received a single infusion of 15 mg/kg upon re-treatment. PD response of B-cells was also evaluated after initial treatment and after re-treatment.

Thirty-eight patients have entered the re-treatment study, and re-treatment data were available for 36 patients with some patients having received six courses of TRU-015
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
2. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
6. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
7. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
8. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
9. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
10. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- RadiologyAuction will have their first auction starting May 5 ... the end of the auction on May 27 th ... Cr,s, Agfa and Sony, printers and GE portable x-rays ... equipment will be available at later auctions each month ... buying and selling imaging equipment, the brokers at RadiologyAuction ...
(Date:5/4/2015)... -- Makindus, Inc. a specialty pharmaceutical development company focused on ... has granted orphan drug designation for their lead candidate, ... "We are extremely pleased to now have orphan drug ... for Europe . This complements and ... States for which orphan designation has already ...
(Date:5/4/2015)... , May 4, 2015   HeartWare International, Inc ... invasive, miniaturized circulatory support technologies that are revolutionizing the treatment ... Doug Godshall , is scheduled to present at the ... Las Vegas on Thursday, May 14, ... The live webcast of the Company,s presentation at the conference ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... As part of the Help America ... the first approved candidate with hearing instruments at no ... came into the Beaverton clinic because of hearing concerns. ... those that have hearing loss and limited financial resources ...
... Spectrum Control, Inc. (Nasdaq: SPEC ), a leading ... today that it will release its fourth quarter and fiscal ... close of the market. Following the release, Spectrum Control will ... discuss the Company,s operating results for the quarter and fiscal ...
Cached Medicine Technology:Accurate Hearing & Audiology Clinics / Help America Hear - One Person at a Time 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 The U.S. ... baby boomers join the ranks of senior citizens (1) ... on an already over-burdened healthcare system. Additionally, as older ... to replace them. Per the U.S. Census Bureau, the ... to increase 75% by 2050 while those 25 to ...
(Date:5/4/2015)... WA (PRWEB) May 04, 2015 EyeCRO ... a collaboration to facilitate development of NM108, a first-in-class ... that lead to blindness, including Diabetic Retinopathy. The ... platform developed by EyeCRO, which can deliver drugs to ... topical eyedrop. , Under the terms of the ...
(Date:5/4/2015)... Ill., (PRWEB) May 04, 2015 New ... American Brain Tumor Association (ABTA) show that people diagnosed ... diagnosis and treatment options, including clinical trials, at the ... days to make difficult decisions about their course of ... launch of the first nationwide brain tumor volunteer network, ...
(Date:5/4/2015)... May 04, 2015 Sheltering Arms announced ... from Hale House. The Mother Hale Learning Center meets ... Early Childhood Education. Sheltering Arms will begin operating the ... be served by the center. , Opened in 2006, ... six weeks to five years, many of whom come ...
(Date:5/4/2015)... May 04, 2015 Elisabeth Rosenthal’s ... a stir and showed the healthcare fraternity as ... healthcare procedure, the downside of balance billing. In ... healthcare provider billing a patient for the difference ... reimburse and what the provider chooses to charge. ...
Breaking Medicine News(10 mins):Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3
... Saturday staged the Gay Pride parade in Rome, urging ... couples legal status and override Vatican objections . ... and lawmakers, marched under a baking sun from Rome's ... Lateran, the official ecclesiastical seat of the Pope as ...
... non-invasive screening in early pregnancy reduces Down's syndrome ... Brndum-Nielsen, of the Kennedy Institute, Glostrup, Denmark, has ... ultrasound early in pregnancy, combined with maternal blood ... in Denmark with Down Syndrome by 50 percent. ...
... has identified a gene responsible for otosclerosis - the ... adults . ,Melissa Thys, from the Department ... this finding may be a step towards new treatments ... ,Otosclerosis is a multifactorial disease, caused by ...
... study has found that waiting just two minutes to cut ... health boost as it reduces the risk of blood disorders ... McMaster University in Hamilton, Canada, and involved more than 1,900 ... the university, said that the results showed that as little ...
... partly to blame for the conflict in Sudan's Darfur ... U.N. Secretary-General Ban Ki-moon said in an editorial published ... in convenient military and political shorthand - an ethnic ... Ban wrote in The Washington Post. "Look to its ...
... The researchers identified individual genes that are associated with ... future studies that may significantly enhance the ability to ... respond to treatment,using a functional genomic screen. ... treatment failure in patients with metastatic cancer. Dr. Julian ...
Cached Medicine News:Health News:Gay Pride Attracts Tens of Thousands in Rome 2Health News:Non-invasive Screening in Early Pregnancy Halves Down's Syndrome Births 2Health News:Boffin Identifies Gene Causing Otosclerosis 2Health News:2 Minute Delay in Cutting Cord can Give Babies a 'significant' Health Boost 2Health News:Climatic Change Cause of Dafur Conflict-UN 2Health News:New Genetic Studies Carried Out in Cancer Therapy 2
4 hour identification of over 70 medically important, oxidase-negative, gram-negative bacilli, including E. coli, based on enzyme technology....
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A direct qualitative enzyme immunoassay for detection of E.coli Shiga Toxin 1 and 2 in fresh or preserved fecal specimens....
Medicine Products: